@article{99879f02eb7140029bf2edda39b75689,
title = "Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count",
abstract = "Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.",
keywords = "AIDS-Related Opportunistic Infections, Adult, Anti-HIV Agents, Antifungal Agents, CD4 Lymphocyte Count, Europe, Female, HIV Infections, Humans, Incidence, Male, Middle Aged, Pneumocystis jirovecii, Pneumonia, Pneumocystis, Risk Factors",
author = "Amanda Mocroft and Peter Reiss and Ole Kirk and Cristina Mussini and Enrico Girardi and Philippe Morlat and Christoph Stephan and {De Wit}, Stephane and Katja Doerholt and Jade Ghosn and Bucher, {Heiner C} and Lundgren, {Jens D} and Genevieve Chene and Miro, {Jose M} and Hansjakob Furrer and {Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)}",
year = "2010",
month = sep,
day = "1",
doi = "10.1086/655761",
language = "English",
volume = "51",
pages = "611--9",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",
}